Pricing the EpiPen: Drug Prices, Corporate Governance, and the Financialization of Biomedicine

danyaglabauOctober 12, 2016December 9, 2016Research, Writing

Why does Mylan’s EpiPen cost so much? Read my early-stage reflections on the matter over at Somatosphere in a recent blog post.

3 Comments

Pingback: Pricing the EpiPen: Drug Prices, Corporate Governance, and the Financialization of Biomedicine — Danya Glabau | political economy of technoscience
keanbirch says:

October 13, 2016 at 8:42 am

Just reposted at https://politicaleconomyoftechnoscience.wordpress.com/ – hope that’s ok

Reply
1. danyaglabau says:
  
  October 13, 2016 at 8:43 am
  
  Thanks, Kean!

Respond to this post Cancel reply